Benefit of postoperative adjuvant therapy for pancreatic cancer

A population-based analysis

Kimberly A. Vanderveen, Steven L. Chen, Daixin Yin, Rosemary D Cress, Richard J Bold

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND: Despite the recent completion of several trials of adjuvant therapy after resection for pancreatic adenocarcinoma, the absolute impact on survival and the identification of appropriate patients for treatment has remained controversial. In the current study, the authors sought to identify the impact of adjuvant therapy and factors associated with any improvement in survival after resection of pancreatic cancer. METHODS: Through the California Cancer Registry, all California residents diagnosed with pancreatic cancer between 1994 and 2002 were identified. Factors potentially impacting survival were analyzed, including patient demographics, tumor characteristics, and treatment provided. Univariate and multivariate survival analyses were performed by Kaplan-Meier and Cox regression methods. RESULTS: A total of 26,518 patients were identified; 3196 (12.1%) underwent resection as their primary treatment. The median overall survival was 16 months for patients who underwent resection. Prognostic factors associated with better survival included negative lymph node status, well-differentiated tumors, younger age, female sex, and the receipt of any adjuvant therapy. On multivariate analysis, adjuvant therapy demonstrated a statistically significant, although modest, impact on survival, with a hazards ratio of 0.79 (95% confidence interval, 0.72-0.87; P < .001). The benefit of adjuvant therapy was only apparent in those patients with lymph node-positive or poorly differentiated tumors. CONCLUSIONS: Adjuvant therapy provided for a modest improvement in overall survival after surgical resection of pancreatic cancer. The absolute effect was most pronounced in those patients with poor prognostic indicators. To identify effective systemic therapy for this deadly cancer, future clinical trials of adjuvant therapy should focus on these groups of patients.

Original languageEnglish (US)
Pages (from-to)2420-2429
Number of pages10
JournalCancer
Volume115
Issue number11
DOIs
StatePublished - Jun 1 2009

Fingerprint

Pancreatic Neoplasms
Population
Survival
Therapeutics
Neoplasms
Multivariate Analysis
Lymph Nodes
Survival Analysis
Focus Groups
Registries
Adenocarcinoma
Demography
Clinical Trials
Confidence Intervals

Keywords

  • Adjuvant treatment
  • Outcomes
  • Pancreatic cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Benefit of postoperative adjuvant therapy for pancreatic cancer : A population-based analysis. / Vanderveen, Kimberly A.; Chen, Steven L.; Yin, Daixin; Cress, Rosemary D; Bold, Richard J.

In: Cancer, Vol. 115, No. 11, 01.06.2009, p. 2420-2429.

Research output: Contribution to journalArticle

Vanderveen, Kimberly A. ; Chen, Steven L. ; Yin, Daixin ; Cress, Rosemary D ; Bold, Richard J. / Benefit of postoperative adjuvant therapy for pancreatic cancer : A population-based analysis. In: Cancer. 2009 ; Vol. 115, No. 11. pp. 2420-2429.
@article{05ed8c8c691a443ea2443a1df3fc64dd,
title = "Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis",
abstract = "BACKGROUND: Despite the recent completion of several trials of adjuvant therapy after resection for pancreatic adenocarcinoma, the absolute impact on survival and the identification of appropriate patients for treatment has remained controversial. In the current study, the authors sought to identify the impact of adjuvant therapy and factors associated with any improvement in survival after resection of pancreatic cancer. METHODS: Through the California Cancer Registry, all California residents diagnosed with pancreatic cancer between 1994 and 2002 were identified. Factors potentially impacting survival were analyzed, including patient demographics, tumor characteristics, and treatment provided. Univariate and multivariate survival analyses were performed by Kaplan-Meier and Cox regression methods. RESULTS: A total of 26,518 patients were identified; 3196 (12.1{\%}) underwent resection as their primary treatment. The median overall survival was 16 months for patients who underwent resection. Prognostic factors associated with better survival included negative lymph node status, well-differentiated tumors, younger age, female sex, and the receipt of any adjuvant therapy. On multivariate analysis, adjuvant therapy demonstrated a statistically significant, although modest, impact on survival, with a hazards ratio of 0.79 (95{\%} confidence interval, 0.72-0.87; P < .001). The benefit of adjuvant therapy was only apparent in those patients with lymph node-positive or poorly differentiated tumors. CONCLUSIONS: Adjuvant therapy provided for a modest improvement in overall survival after surgical resection of pancreatic cancer. The absolute effect was most pronounced in those patients with poor prognostic indicators. To identify effective systemic therapy for this deadly cancer, future clinical trials of adjuvant therapy should focus on these groups of patients.",
keywords = "Adjuvant treatment, Outcomes, Pancreatic cancer, Survival",
author = "Vanderveen, {Kimberly A.} and Chen, {Steven L.} and Daixin Yin and Cress, {Rosemary D} and Bold, {Richard J}",
year = "2009",
month = "6",
day = "1",
doi = "10.1002/cncr.24269",
language = "English (US)",
volume = "115",
pages = "2420--2429",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Benefit of postoperative adjuvant therapy for pancreatic cancer

T2 - A population-based analysis

AU - Vanderveen, Kimberly A.

AU - Chen, Steven L.

AU - Yin, Daixin

AU - Cress, Rosemary D

AU - Bold, Richard J

PY - 2009/6/1

Y1 - 2009/6/1

N2 - BACKGROUND: Despite the recent completion of several trials of adjuvant therapy after resection for pancreatic adenocarcinoma, the absolute impact on survival and the identification of appropriate patients for treatment has remained controversial. In the current study, the authors sought to identify the impact of adjuvant therapy and factors associated with any improvement in survival after resection of pancreatic cancer. METHODS: Through the California Cancer Registry, all California residents diagnosed with pancreatic cancer between 1994 and 2002 were identified. Factors potentially impacting survival were analyzed, including patient demographics, tumor characteristics, and treatment provided. Univariate and multivariate survival analyses were performed by Kaplan-Meier and Cox regression methods. RESULTS: A total of 26,518 patients were identified; 3196 (12.1%) underwent resection as their primary treatment. The median overall survival was 16 months for patients who underwent resection. Prognostic factors associated with better survival included negative lymph node status, well-differentiated tumors, younger age, female sex, and the receipt of any adjuvant therapy. On multivariate analysis, adjuvant therapy demonstrated a statistically significant, although modest, impact on survival, with a hazards ratio of 0.79 (95% confidence interval, 0.72-0.87; P < .001). The benefit of adjuvant therapy was only apparent in those patients with lymph node-positive or poorly differentiated tumors. CONCLUSIONS: Adjuvant therapy provided for a modest improvement in overall survival after surgical resection of pancreatic cancer. The absolute effect was most pronounced in those patients with poor prognostic indicators. To identify effective systemic therapy for this deadly cancer, future clinical trials of adjuvant therapy should focus on these groups of patients.

AB - BACKGROUND: Despite the recent completion of several trials of adjuvant therapy after resection for pancreatic adenocarcinoma, the absolute impact on survival and the identification of appropriate patients for treatment has remained controversial. In the current study, the authors sought to identify the impact of adjuvant therapy and factors associated with any improvement in survival after resection of pancreatic cancer. METHODS: Through the California Cancer Registry, all California residents diagnosed with pancreatic cancer between 1994 and 2002 were identified. Factors potentially impacting survival were analyzed, including patient demographics, tumor characteristics, and treatment provided. Univariate and multivariate survival analyses were performed by Kaplan-Meier and Cox regression methods. RESULTS: A total of 26,518 patients were identified; 3196 (12.1%) underwent resection as their primary treatment. The median overall survival was 16 months for patients who underwent resection. Prognostic factors associated with better survival included negative lymph node status, well-differentiated tumors, younger age, female sex, and the receipt of any adjuvant therapy. On multivariate analysis, adjuvant therapy demonstrated a statistically significant, although modest, impact on survival, with a hazards ratio of 0.79 (95% confidence interval, 0.72-0.87; P < .001). The benefit of adjuvant therapy was only apparent in those patients with lymph node-positive or poorly differentiated tumors. CONCLUSIONS: Adjuvant therapy provided for a modest improvement in overall survival after surgical resection of pancreatic cancer. The absolute effect was most pronounced in those patients with poor prognostic indicators. To identify effective systemic therapy for this deadly cancer, future clinical trials of adjuvant therapy should focus on these groups of patients.

KW - Adjuvant treatment

KW - Outcomes

KW - Pancreatic cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=66649112508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649112508&partnerID=8YFLogxK

U2 - 10.1002/cncr.24269

DO - 10.1002/cncr.24269

M3 - Article

VL - 115

SP - 2420

EP - 2429

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -